Related Experiment Videos

PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance

Mariacarmela Santarpia1, Giuseppe Altavilla, Mireia Margeli

  • 1Human Pathology Department, Medical Oncology Unit, University of Messina, Italy.

Cancer Investigation
|September 18, 2008
PubMed

Insights

PIK3CA mutations are common in breast cancer and linked to older patients. Higher BRCA1 mRNA expression correlates with advanced disease and ERBB2 overexpression, potentially guiding taxane chemotherapy selection.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • PIK3CA mutations and BRCA1 alterations are frequent in breast cancer.
  • These genetic changes may influence taxane sensitivity and patient outcomes.

Purpose of the Study:

  • To investigate the relationship between PIK3CA mutations and BRCA1 mRNA expression in breast cancer patients.
  • To correlate these genetic factors with clinical and pathological features.

Main Methods:

  • Genomic DNA was analyzed for PIK3CA mutations at hotspots (E542K, E545K, H1047R).
  • Intratumoral BRCA1 mRNA expression was quantified using quantitative RT-PCR.
  • Data from 61 breast cancer patients were analyzed.

Main Results:

  • PIK3CA mutations were identified in 27.9% of patients and did not correlate with BRCA1 levels.
  • PIK3CA mutations showed a significant association with older patient age (P = 0.03).
  • Higher BRCA1 mRNA expression correlated with advanced disease (P = 0.01) and ERBB2 overexpression (P = 0.02).

Conclusions:

  • These genetic markers may help stratify breast cancer patients.
  • Findings could aid in identifying patients likely to benefit from microtubule-disrupting agents like taxanes.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...